About This Trial

mRNA therapy encoding PCCA and PCCB enzymes for this life-threatening metabolic disorder.

Primary Endpoints

  • Safety
  • Reduction in metabolic decompensation events

Latest Update

January 2026

All 12 patients in dose-escalation phase showed reduced plasma biomarkers. No serious adverse events reported.